[go: up one dir, main page]

ES2182843T3 - Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso. - Google Patents

Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso.

Info

Publication number
ES2182843T3
ES2182843T3 ES94916547T ES94916547T ES2182843T3 ES 2182843 T3 ES2182843 T3 ES 2182843T3 ES 94916547 T ES94916547 T ES 94916547T ES 94916547 T ES94916547 T ES 94916547T ES 2182843 T3 ES2182843 T3 ES 2182843T3
Authority
ES
Spain
Prior art keywords
subunities
nmda
nucleic acids
receiving
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916547T
Other languages
English (en)
Inventor
Lorrie P Daggett
Steven B Ellis
Chen Wang Liaw
Chin-Chun Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21977682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2182843(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2182843T3 publication Critical patent/ES2182843T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of El Displays (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

DE ACUERDO CON LA PRESENTE INVENCION, SE PROPORCIONAN ACIDOS NUCLEICOS QUE CODIFICAN SUBUNIDADES DE PROTEINA RECEPTORA DE NMDA HUMANO Y LAS PROTEINAS CODIFICADAS POR LOS MISMOS. LAS SUBUNIDADES RECEPTORAS DE NMDA DE LA INVENCION COMPRENDEN COMPONENTES DE RECEPTORES DE NMDA QUE TIENEN CANALES DE CATION SELECTIVOS Y GLUTAMATO DE ENLACE Y NMDA. EN UN ASPECTO DE LA INVENCION, LOS ACIDOS NUCLEICOS CODIFICAN SUBUNIDADES DE NMDAR1 Y NMDAR2 DE RECEPTORES DE NMDA HUMANOS. EN UNA REALIZACION PREFERIDA, LOS ACIDOS NUCLEICOS DE LA INVENCION CODIFICAN SUBUNIDADES NMDAR1, NMDAR2A, NMDAR2B, NMDAR2C Y NMDAR2D DE RECEPTORES DE NMDA HUMANO. ADEMAS AL SER UTILES PARA LA PRODUCCION DE SUBUNIDADES DE PROTEINAS RECEPTORAS DE NMDA, ESTOS ACIDOS NUCLEICOS SON TAMBIEN UTILES COMO SONDAS, PERMITIENDO ASI A AQUELLOS EXPERTOS EN LA MATERIA, SIN EXPERIMENTACION INDEBIDA, IDENTIFIQUEN Y AISLEN SUBUNIDADES RECEPTORAS HUMANAS RELACIONADAS. RECEPTORES DE GLUTAMATO FUNCIONAL PUEDEN INCORPORARSE, DE ACUERDO CON LA PRESENTE INVENCION, A PARTIR DE UNA PLURALIDAD DE UN TIPO DE PROTEINA DE SUBUNIDAD RECEPTORA DE NMDA (HOMOMERICA) O A PARTIR DE UNA MEZCLA DE DOS O MAS TIPOS DE PROTEINAS DE SUBUNIDAD (HETEROMERICA). ADEMAS DE DESCUBRIR NUEVAS SUBUNIDADES DE PROTEINA RECEPTORA DE NMDA, LA PRESENTE INVENCION TAMBIEN COMPRENDE METODOS PARA UTILIZAR TALES SUBUNIDADES RECEPTORAS PARA IDENTIFICAR Y CARACTERIZAR COMPUESTOS QUE AFECTAN LA FUNCION DE TALES RECEPTORES, POR EJEMPLO, AGONISTAS, ANTAGONISTAS, Y MODULADORES DE FUNCION RECEPTORA DE GLUTAMATO. LA INVENCION TAMBIEN COMPRENDE METODOS PARA DETERMINAR SI PROTEINA(S) DESCONOCIDA SON FUNCIONALES COMO SUBUNIDADES RECEPTORAS DE NMDA.
ES94916547T 1993-04-20 1994-04-20 Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso. Expired - Lifetime ES2182843T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5244993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
ES2182843T3 true ES2182843T3 (es) 2003-03-16

Family

ID=21977682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94916547T Expired - Lifetime ES2182843T3 (es) 1993-04-20 1994-04-20 Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso.

Country Status (10)

Country Link
US (11) US5849895A (es)
EP (1) EP0696320B1 (es)
JP (1) JPH08509607A (es)
AT (1) ATE224952T1 (es)
AU (1) AU696922B2 (es)
CA (1) CA2159106C (es)
DE (1) DE69431432T2 (es)
ES (1) ES2182843T3 (es)
GB (1) GB2286188B (es)
WO (1) WO1994024284A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2110934A1 (en) 1992-12-11 1994-06-12 Robert L. Foldes Human cns receptors of the nmda-r1 family
AU696922B2 (en) 1993-04-20 1998-09-24 Merck & Co., Inc. Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
EP0674003A3 (en) * 1994-03-25 1997-09-10 Allelix Biopharma Modulators of receptors in the human central nervous system.
GB9414997D0 (en) * 1994-07-26 1994-09-14 Merck Sharp & Dohme Receptor cloning
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US6822084B1 (en) * 1999-06-25 2004-11-23 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding stress, resistance and tolerance proteins
US20040204490A1 (en) * 1999-08-31 2004-10-14 Farb David H. Effect of steroids on NMDA receptors depends on subunit composition
ATE425459T1 (de) * 1999-08-31 2009-03-15 Univ Boston Der effekt von steroiden auf ndma-rezeptoren beruht auf der zusammensetzung der untereinheiten
US6916816B2 (en) * 1999-12-16 2005-07-12 The Board Of Regents Of The University Of Nebraska Phenanthryl piperazinyl dicarboxylic acids as selective NMDA receptor modulating agents
GB9929582D0 (en) * 1999-12-16 2000-02-09 Univ Bristol Chemical compounds
US20030092071A1 (en) * 2000-02-01 2003-05-15 Jasna Jerecic Interaction of NMDA receptor with protein tyrosine phosphatase
US6521414B2 (en) * 2000-02-01 2003-02-18 Agy Therapeutics, Inc. Methods for identifying a modulator of the interaction of NMDA receptor with protein tyrosine phosphatase L1
JP4037268B2 (ja) * 2001-01-30 2008-01-23 塩野義製薬株式会社 ヒトｎｍｄａレセプタースプライスバリアント
US6896872B2 (en) * 2001-06-27 2005-05-24 Svetlana A. Dambinova Rapid multiple panel of biomarkers in laboratory blood tests for TIA/stroke
WO2003010540A1 (en) * 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US6701482B2 (en) * 2001-09-20 2004-03-02 Qualcomm Incorporated Method and apparatus for coding bits of data in parallel
ES2541351T3 (es) 2002-02-25 2015-07-17 Vaxiion Therapeutics, Llc Composiciones de minicélulas y procedimientos
US6884473B2 (en) * 2002-12-24 2005-04-26 Macronix International Co., Ltd. Method for fabricating metal silicide
US7354834B2 (en) * 2003-06-04 2008-04-08 Dongbu Electronics Co., Ltd. Semiconductor devices and methods to form trenches in semiconductor devices
US20050202407A1 (en) * 2003-12-01 2005-09-15 Baylor College Of Medicine Methods and assays for screening anti-neoplastic therapeutic agents
US20060257943A1 (en) * 2005-01-25 2006-11-16 Cis Biotech, Inc. Ischemic biomarkers and their use to predict adverse neurological events from surgery
ATE487947T1 (de) * 2005-06-13 2010-11-15 Cis Biotech Inc Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
WO2007006157A1 (en) * 2005-07-14 2007-01-18 The University Of British Columbia Neuroprotective modulation of nmda receptor subtype activities
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
US20100210816A1 (en) * 2006-12-12 2010-08-19 Svetlana Dambinova NMDAR Biomarkers for Diagnosing and Treating Cerebral Ischemia
US20100316678A1 (en) * 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
CN102223791A (zh) 2008-09-27 2011-10-19 塔阿克斯有限公司 用于神经病变治疗的局部用制剂
WO2017109709A2 (en) * 2015-12-22 2017-06-29 Novartis Ag A high-throughput assay method for identifying allosteric nmda receptor modulators
RU2668534C1 (ru) * 2017-07-18 2018-10-01 Общество с ограниченной ответственностью "ДРД" Диагностический набор реагентов для выявления хронических патологий мозга ишемического генеза

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US4929555A (en) * 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2215986T3 (es) * 1989-10-27 2004-10-16 The Salk Institute For Biological Studies Composiciones receptoras de glutamato y metodos.
US5028707A (en) * 1989-11-20 1991-07-02 Board Of Regents, University Of Texas 4-hydroxyquinaldic acid derivatives
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5146257A (en) 1991-02-19 1992-09-08 Minnesota Mining And Manufacturing Company Developer solution replenishment control system for a digital imaging system
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5502168A (en) * 1991-10-24 1996-03-26 The Johns Hopkins University Monoclonal antibodies to a continuous and cross-reactive epitope and an isolated protein of a sexual stage of P. falciparum
US5670113A (en) * 1991-12-20 1997-09-23 Sibia Neurosciences, Inc. Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same
JP3400470B2 (ja) * 1992-08-12 2003-04-28 三菱化学株式会社 新規なタンパク質およびそれをコードする遺伝子
JPH0614783A (ja) * 1992-06-30 1994-01-25 Mitsubishi Kasei Corp 新規なタンパク質およびそれをコードする遺伝子
JP3353841B2 (ja) * 1992-11-13 2002-12-03 三菱化学株式会社 新規なタンパク質およびそれをコードする遺伝子
US5502166A (en) * 1992-02-26 1996-03-26 Mitsubishi Chemical Corporation NMDH receptor proteins and genes encoding the same
DE4216321A1 (de) * 1992-05-16 1993-11-18 Basf Ag Untereinheiten von NMDA-Rezeptoren, Verfahren zu ihrer Herstellung und ihre Verwendung
DK68592D0 (da) * 1992-05-25 1992-05-25 Novo Nordisk As Celle
FR2692268B1 (fr) * 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
DE4222826A1 (de) * 1992-07-09 1994-01-13 Schering Ag Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen
DE4227657A1 (de) 1992-08-21 1994-02-24 Hydac Technology Gmbh Ultraschall-Prüfeinrichtung für Gasdruckspeicher
GB9307026D0 (en) 1993-04-02 1993-05-26 Merck Sharp & Dohme Receptor cloning
US6130058A (en) * 1992-11-12 2000-10-10 Merck Sharpe & Dohme Ltd. Human NMDA R2A receptor subunit and isoforms of the human NMDA-R1 receptor subunit and encoding cDNAs
GB9223769D0 (en) 1992-11-12 1992-12-23 Merck Sharp & Dohme Receptor cloning
CA2110934A1 (en) * 1992-12-11 1994-06-12 Robert L. Foldes Human cns receptors of the nmda-r1 family
AU696922B2 (en) * 1993-04-20 1998-09-24 Merck & Co., Inc. Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor
US5364590A (en) 1993-05-07 1994-11-15 American Sterlizer Company Method for sterilization of objects
EP0674003A3 (en) * 1994-03-25 1997-09-10 Allelix Biopharma Modulators of receptors in the human central nervous system.
DE4410882A1 (de) * 1994-03-29 1995-10-05 Basf Ag Verfahren zur permanenten Expression von Glutamatrezeptoren
GB9414997D0 (en) * 1994-07-26 1994-09-14 Merck Sharp & Dohme Receptor cloning

Also Published As

Publication number Publication date
GB9503689D0 (en) 1995-04-12
US6469142B1 (en) 2002-10-22
GB2286188B (en) 1997-11-12
AU696922B2 (en) 1998-09-24
US6376660B1 (en) 2002-04-23
US5985586A (en) 1999-11-16
DE69431432T2 (de) 2003-04-24
WO1994024284A1 (en) 1994-10-27
US6111091A (en) 2000-08-29
US6956102B2 (en) 2005-10-18
US6521413B1 (en) 2003-02-18
AU6817594A (en) 1994-11-08
JPH08509607A (ja) 1996-10-15
EP0696320A1 (en) 1996-02-14
US20020161215A1 (en) 2002-10-31
US6316611B1 (en) 2001-11-13
CA2159106A1 (en) 1994-10-27
US6825322B2 (en) 2004-11-30
CA2159106C (en) 2009-10-06
DE69431432D1 (de) 2002-10-31
EP0696320B1 (en) 2002-09-25
US5849895A (en) 1998-12-15
GB2286188A (en) 1995-08-09
ATE224952T1 (de) 2002-10-15
US6033865A (en) 2000-03-07
US20030013866A1 (en) 2003-01-16
US6864358B2 (en) 2005-03-08
US20020161193A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2182843T3 (es) Subunidades de receptor humano de n-metil-d-aspartato, acidos nucleicos que codifican las mismas y su uso.
NO20003115D0 (no) Høyeffektivt analysesystem
WO2003002750A3 (en) High throughput assay system
EA200200062A1 (ru) Высокопроизводительная тест-система
GB2324628B (en) Manufacturing functional testing of computing devices using microprogram based functional tests applied via the devices own emulation debug port
BR9815581A (pt) Conjuntos de nanoeletrodos
FI890526A0 (fi) Analyyttikonsentraation määritys käyttäen kahta leimausainetta
BR8501445A (pt) Ferramenta para uso em uma coluna de teste disposta em um furo de poco ferramenta de teste de multiplos modos,conjunto de catraca,conjunto operante para uma ferramenta de descida em poco,conjunto indexador,valvula de deslocamento processo de operar uma ferramenta de descida em poco e conjunto de operacao para uma ferramenta de descida em poco
WO2000037683A3 (en) HIGH THROUGHPUT ASSAY SYSTEM FOR MONITORING ESTs
DE69027325D1 (de) Handgehaltene mehrkanälige pipettierungsvorrichtung
BR7802225A (pt) Processo para determinacao de uma substancia de ligacao especifica em uma amostra de liquido,e dispositivo de teste para o mesmo
DE3787078D1 (de) Proberichtwirkung fuer analytisches festphasengeraet.
DE69830255D1 (de) Testeinheit zur Prüfung von Steckverbindern
ATE263375T1 (de) Multiple analyse von zytokinen
DE69800628D1 (de) Verschlussvorrichtung fur ein reagenzglas verwendbar in einem analyseapparat
ES2057571T3 (es) Receptor de pdgf-alfa.
BR9200851A (pt) Teste de tracao laboratorial
AU576982B2 (en) In-circuit emulator probe
IL83521A0 (en) Improved probe for composite analyser tester
ES2170056T3 (es) Sistemas de analisis de la actividad de la neurotrofina.
DE69023313D1 (de) Prüfstand mit Dynamometer.
DE59006427D1 (de) Mehrkomponenten-Kraftmessanordnung ohne Messplatte.
DE3784468D1 (de) Testbares mehrmodus-zaehlernetz und methode zur durchfuehrung des tests.
DE69015372D1 (de) Protein-testverfahren.
DK228686D0 (da) Kopformet apparat indeholdende mindst to ublandbare vaesker, til selektiv vaesketilfoersel til et analyseringsinstrument